TearSolutions has landed two FDA designations for Lacripep, a topical synthetic peptide that could become the first targeted treatment for a rare and painful corneal disease. The agency granted both Orphan Drug and Fast Track status. Phase two dosing has already started.
This is the kind of peptide story that gets lost behind GLP-1 headlines. A small biotech. A first-in-class mechanism. A disease with no approved therapy. And a peptide discovered not in a pharma lab but in an academic screen of human tear proteins.
What Lacripep Is and Why It Matters
Lacripep is a synthetic fragment of lacritin, a one-hundred-nineteen-amino-acid protein found naturally in human tears. Researchers at the University of Virginia discovered it through an unbiased screen funded by the National Institutes of Health National Eye Institute. The peptide has a dual mechanism. It promotes nerve repair and it reactivates the eye’s own tear production machinery.
The target indication is neurotrophic keratitis, or NK. In NK, the cornea loses sensitivity. The surface cannot heal itself. Patients develop persistent epithelial defects. Some lose vision. There is no approved drug for this condition in the United States. That explains why the FDA handed out two designations at once.
The Regulatory Path and What Comes Next
Orphan Drug Designation brings tax credits for clinical testing and seven years of market exclusivity upon approval. Fast Track means more frequent FDA meetings and the option for a rolling drug application review. Getting both at the same time is a clear signal. The agency sees an unmet need and wants this program to move.
The phase two trial is now underway. It is a multicenter, randomized, vehicle-controlled study with about fifty-four patients. The trial identifier is NCT07568730. TearSolutions CEO Anil Asrani called the dual designations a significant milestone that validates the company’s approach to transforming NK treatment.
Expert Insight
But what most people miss about topical peptide therapeutics is the formulation challenge. Peptides do not easily cross the corneal epithelium. A peptide that looks active in a dish can be useless in an eye drop if the formulation does not solve the delivery problem. The fact that Lacripep has advanced to phase two with the FDA’s encouragement suggests TearSolutions has cracked something real here.
What experienced teams know is that ophthalmic peptides occupy a strategic sweet spot. The eye is an immune-privileged site. Systemic exposure from a topical drop is minimal. That means safety concerns that derail systemic peptide programs are far less likely. Lacripep may have a cleaner regulatory path than most peptide drugs.
So what does this mean for peptide drug developers watching from the sidelines? One clear lesson is that academic discovery pipelines still produce winning peptide candidates. Lacritin was found in a basic science screen. It was not engineered by a platform company. The field should not overlook publicly funded research as a source of clinical-stage peptides.
The natural question is whether the dry eye disease program will follow. TearSolutions previously told Ophthalmology Times it plans phase two-three trials in dry eye, including in patients with primary Sjogren syndrome. A positive phase two readout in NK would substantially de-risk that larger program. The peptide could address two multi-billion-dollar ophthalmic markets from a single mechanism.
Another question worth asking is about manufacturing. Lacritin-derived peptides are not trivial to produce at scale. The company has not disclosed its synthesis route or CMO partnerships. As the program advances toward registration, manufacturing readiness will become the rate-limiting step. That is a pattern every peptide biotech faces eventually.
Further Reading
- Cenna Nubytide Peptide Takes Aim at Amyloid Production in Alzheimer’s
- Parabilis IPO Validates Intracellular Peptide Technology
- FDA Moves to Reclassify 12 Peptides in Major Regulatory Shift
Last reviewed: June 2026. Peptide Proof Editorial Team. Sources: Ophthalmology Times, TearSolutions Press Release
